The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?

被引:186
作者
Mercuri, NB
Bernardi, G
机构
[1] Univ Roma Tor Vergata, Neurol Clin, I-00179 Rome, Italy
[2] Fdn Santa Lucia, IRCCS, I-00179 Rome, Italy
关键词
D O I
10.1016/j.tips.2005.05.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The chronic treatment of Parkinson's disease with L-dopa is often associated with fluctuations of motor response and dyskinesias. Therefore, to overcome the adverse effects of the long-term use Of L-dopa, directly acting dopamine receptor agonists have been introduced. However, L-dopa remains the most effective treatment of the slowness of movement, increased muscle tone, and tremor that are typical of Parkinson's disease. Why is this so? In this article, we discuss evidence that suggests that dopamine produced from L-dopa has a larger number of actions compared with dopamine receptor agonists. In addition to stimulating D-1- and D-2-like dopamine receptors, dopamine might also activate adrenoceptors, novel dopamine sites, the dopamine transporter and trace amine receptors, all of which might contribute to the superior effect Of L-dopa in Parkinson's disease.
引用
收藏
页码:341 / 344
页数:4
相关论文
共 40 条
[1]   BIOCHEMISTRY OF PARKINSONS-DISEASE 28 YEARS LATER - A CRITICAL-REVIEW [J].
AGID, Y ;
CERVERA, P ;
HIRSCH, E ;
JAVOYAGID, F ;
LEHERICY, S ;
RAISMAN, R ;
RUBERG, M .
MOVEMENT DISORDERS, 1989, 4 :S126-S144
[2]   Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia [J].
Aubert, I ;
Guigoni, C ;
Håkansson, K ;
Li, Q ;
Dovero, S ;
Barthe, N ;
Bioulac, BH ;
Gross, CE ;
Fisone, G ;
Bloch, B ;
Bezard, E .
ANNALS OF NEUROLOGY, 2005, 57 (01) :17-26
[3]   Action of beta-phenylethylamine and related amines on nigrostriatal dopamine neurotransmission [J].
Barroso, N ;
Rodriguez, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 297 (03) :195-203
[4]  
Birkmayer W, 1998, Parkinsonism Relat Disord, V4, P59, DOI 10.1016/S1353-8020(98)00013-3
[5]   Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients [J].
Blanchet, PJ ;
Allard, P ;
Gregoire, L ;
Tardif, F ;
Bedard, PJ .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1996, 23 (03) :189-193
[6]  
CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433
[7]   Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease [J].
Clarke, CE .
LANCET NEUROLOGY, 2004, 3 (08) :466-474
[8]   Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET [J].
Cools, R ;
Stefanova, E ;
Barker, RA ;
Robbins, TW ;
Owen, AM .
BRAIN, 2002, 125 :584-594
[9]   SIMILARITIES BETWEEN NEUROLOGIC EFFECTS OF L-DOPA AND OF APOMORPHINE [J].
COTZIAS, GC ;
PAPAVASILIOU, PS ;
FEHLING, C ;
KAUFMAN, B ;
MENA, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1970, 282 (01) :31-+
[10]   Presynaptic mechanisms of motor fluctuations in Parkinson's disease:: a probabilistic model [J].
de la Fuente-Fernández, R ;
Schulzer, M ;
Mak, E ;
Calne, DB ;
Stoessl, AJ .
BRAIN, 2004, 127 :888-899